Numab presents updates on ND021 at AACR Annual Meeting 2019

• Report this article

David Urech

David Urech

Biotech Entrepreneur and Board Member

Published Apr 1, 2019

+ Follow

See our poster here:

or visit us at the conference: Poster #1532, Section 25, Board 1

To view or add a comment, sign in

More articles by David Urech

• At a pivotal stage in its growth, Numab secures Series C funding to accelerate a pipeline of multispecific antibodies

  May 20, 2021

  At a pivotal stage in its growth, Numab secures Series C funding to accelerate a pipeline of multispecific antibodies

  A few days ago, a nature review drug discovery article highlighted the fact that 100 therapeutic antibody products have…

  112

  14 Comments
• Numab and CStone today announce regional collaboration on Numab's lead IO program

  May 2, 2019

  Numab and CStone today announce regional collaboration on Numab's lead IO program

  We are very excited to announce today our partnership with CStone Pharmaceuticals on our lead program ND021, a…

  66

  10 Comments
• Numab presents updates on ND021 at AACR Annual Meeting 2019

  Apr 1, 2019

  Numab presents updates on ND021 at AACR Annual Meeting 2019

  Visit our Poster Poster # 1532, Section 25, Board 1

• Numab appoints immunotherapy pioneer Ignacio Melero as scientific advisor

  Sep 20, 2018

  Numab appoints immunotherapy pioneer Ignacio Melero as scientific advisor

  Company progresses development of tri-specific IO therapeutic ND021, which is designed to improve the risk-benefit…

  16
• Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement

  Jun 13, 2017

  Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement

  Pfäffikon, Switzerland, June 13, 2017 - Numab Therapeutics AG ("Numab") today announced a collaboration and option…

  21

  2 Comments

Show more

See all articles